DewCell BioTherapeutics
San Diego, United States· Est.
A US biotech creating stem‑cell derived platelet therapeutics for transfusion medicine.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
A US biotech creating stem‑cell derived platelet therapeutics for transfusion medicine.
Hematology
Technology Platform
Stem‑cell‑derived platelet manufacturing platform that integrates cell line optimization, large‑scale bioreactor cultivation, and GMP‑compliant processes to produce functional, transfusion‑ready platelets and platelet‑like products.
Opportunities
Scalable, on‑demand platelet production can address chronic donor shortages and open new markets in transfusion and wound‑healing therapeutics.
Risk Factors
Regulatory approval pathways for cell‑derived platelet products are complex, and manufacturing scale‑up may encounter technical and cost challenges.
Competitive Landscape
Few companies have demonstrated large‑scale artificial platelet manufacturing; DewCell differentiates through its GMP‑ready platform and multiple product formats.